This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing cancer therapies. The company is employing novel gene expression, and control and cells technologies to deliver cell-based therapies for the treatment of cancer.View ZIOP key stats
ZIOPHARM Oncology Inc - ZIOP - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates ZIOPHARM Oncology Inc as a
Sell with a ratings score of D-.
Report Snippet: We rate ZIOPHARM ONCOLOGY INC (ZIOP) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow and feeble growth in its earnings per share.